Excellent - I now have the full Harrison's algorithm, textbook treatment protocols, and pathogen-specific data. Here is the comprehensive management guide:
Acute Diarrhea Disease - Management Algorithm
Pathophysiology Classification
Classification of diarrhea - Frameworks for Internal Medicine
Step 1 - Initial Assessment: History and Physical
The first branch point is infectious vs. noninfectious.
Features suggesting infectious etiology:
- Acute onset (<14 days)
- Nausea, vomiting, fever
- Epidemiologic clues: recent travel, contaminated food/water, sick contacts, outbreaks (cruise ships, daycare, nursing homes)
- Recent antibiotic use (think C. difficile)
Features suggesting noninfectious etiology:
- New medication (hundreds of drugs cause diarrhea)
- Post-surgical bowel changes
- IBD flare, ischemic colitis, partial obstruction
- Radiation exposure
→ If likely noninfectious: evaluate and treat the underlying cause separately.
Step 2 - Severity Stratification (determines urgency)
| Severity | Description | Action |
|---|
| Mild | Unrestricted daily activity; few loose stools | Observe + oral fluids |
| Moderate | Activities altered; multiple stools; some cramping | ORS + symptomatic treatment |
| Severe | Incapacitated; profuse stool output; dehydration signs | IV rehydration + urgent workup |
Fluid and electrolyte replacement is the cornerstone at ALL severity levels.
Step 3 - Rehydration (Always First)
Oral Rehydration Therapy (ORT)
- Indicated for mild to moderate diarrhea with any dehydration
- Works by Na⁺-glucose co-transport in small bowel (intact even during acute diarrhea)
- WHO ORS formula: ½ tsp salt + 6 tsp sugar + 1 L clean water
- Commercial premixed solutions (e.g., Pedialyte, Ceralyte) are equivalent
- Zinc supplementation (10 mg/day <6 months; 20 mg/day ≥6 months) for children in resource-limited settings - reduces severity, duration, and recurrence
IV Rehydration
- Indicated for severe diarrhea with significant volume depletion, unable to tolerate oral intake, or profoundly dehydrated patients (especially infants and elderly)
- Fluids: Ringer's lactate (preferred) or normal saline
- Transition to ORS as tolerated
Step 4 - Decision: Evaluate or Observe?
Indications for stool microbiological studies (Harrison's Principles of Internal Medicine, 22e):
| Indication | Rationale |
|---|
| Profuse diarrhea with dehydration | Severity demands identification |
| Overtly bloody stools | Invasive pathogen; antibiotic decision needed |
| Fever ≥ 38.5°C | Systemic infection likely |
| Duration >48 h without improvement | Not self-limited |
| Recent antibiotic use | C. difficile possible |
| New community outbreak | Public health implications |
| Severe abdominal pain, age >50 | Ischemia/other pathology |
| Elderly (≥70 yr) or immunocompromised | High-risk host |
If none of the above: observe + symptomatic treatment - most acute diarrhea is self-limited viral gastroenteritis.
Diagnostic Workup (when indicated)
- First-line: Multiplex PCR stool panel - rapid, sensitive, cost-effective; identifies common bacteria, viruses, parasites simultaneously
- Stool culture - used when multiplexed tests unavailable, for outbreak investigation, or antibiotic sensitivity needed
- Fecal leukocytes / calprotectin - elevated = invasive/inflammatory etiology
- C. difficile toxin EIA or PCR - if recent antibiotics, hospitalization, or prolonged course
- Ova and parasites (O&P) - if travel history, immunocompromised, or diarrhea lasting >7-10 days
- Specific cultures - EHEC (O157:H7), Vibrio, Yersinia if clinical clues present
Step 5 - Management Algorithm (Harrison's, Fig. 49-3)
FIGURE 49-3 Algorithm for the management of acute diarrhea. [] = consider empirical metronidazole; [†] = consider empirical quinolone. - Harrison's Principles of Internal Medicine 22e*
Reading the Algorithm:
Acute Diarrhea
↓
History & Physical
↙ ↘
Likely Infectious Likely Noninfectious → Evaluate & Treat
↓
Severity: Mild / Moderate / Severe
↓
FLUID & ELECTROLYTE REPLACEMENT (all patients)
↙ ↘
Mild: Observe Fever ≥38.5°C, bloody stools,
↓ ↑ fecal WBCs, immunocompromised, elderly
Resolves? ↙ ↘
Yes → done No Yes
No → Antidiarrheal Stool Microbiology Studies
agents ↙ ↘
↓ Pathogen Pathogen
Resolves? NOT found Found
Yes → done ↓ ↓
No → ↓ Empirical Tx + Specific Tx
Stool microbiology Further evaluation
Step 6 - Symptomatic (Non-Antibiotic) Treatment
Antimotility Agents
- Loperamide 4 mg initial dose, then 2 mg after each unformed stool (max 16 mg/day)
- Use only in nonfebrile, non-bloody diarrhea (moderate, watery)
- AVOID with:
- Febrile dysentery (prolongs illness)
- Bloody/mucoid stools
- Suspected EHEC O157:H7 or Shigella (may worsen HUS risk)
- C. difficile
Bismuth Subsalicylate
- 524 mg every 30-60 min as needed, up to 8 doses/day
- Useful for mild diarrhea and viral gastroenteritis; reduces nausea and stool frequency
- Avoid in: immunocompromised, renal impairment (bismuth encephalopathy risk)
- Contains salicylate - avoid in children (Reye syndrome risk)
Probiotics
- Not recommended as treatment for acute diarrhea (Goldman-Cecil, 2024)
Step 7 - Antibiotic Therapy
When to use antibiotics:
- Moderate-severe febrile diarrhea
- Bloody diarrhea (invasive pathogen confirmed or suspected - except EHEC)
- Traveler's diarrhea
- Immunocompromised patients (treat regardless of identified organism)
- Mechanical heart valves, recent vascular grafts, elderly
Empiric Regimens
| Indication | First-line | Alternative |
|---|
| Adults - general | Azithromycin 500 mg single dose or 500 mg/day x 3 days | Ciprofloxacin 500 mg q12h x 3-5 days |
| Traveler's diarrhea (noninvasive) | Rifaximin 200 mg TID x 3 days | Azithromycin 1000 mg single dose |
| Traveler's diarrhea (invasive/febrile) | Azithromycin (fluoroquinolone resistance is common in SE Asia) | Ciprofloxacin 500 mg q12h x 3 days (where resistance is low) |
| Suspected Giardia | Metronidazole 250 mg QID x 7 days | Nitazoxanide 500 mg bid x 3 days |
| Children - traveler's | Azithromycin 10 mg/kg (max 500 mg) single dose | - |
Pathogen-Specific Antibiotic Choices
| Pathogen | Treatment | Key Notes |
|---|
| Salmonella (non-typhoidal) | Usually self-limited; no routine antibiotics - prolongs excretion | Treat high-risk: infants <3 mo, immunocompromised, hemoglobinopathy, invasive disease → Ceftriaxone or Ciprofloxacin |
| Typhoid fever (S. Typhi) | Ceftriaxone 50-75 mg/kg/day OR Ciprofloxacin x 10-14 days | Multidrug resistance is common; check susceptibilities; Dexamethasone for delirium/shock |
| Shigella | Azithromycin 20 mg/kg/day (max 500 mg) | Ceftriaxone if unable to take oral; TMP-SMX/ampicillin often resistant |
| Campylobacter | Azithromycin 500 mg/day x 3 days | Can cause Guillain-Barré syndrome (ascending paralysis post-gastroenteritis) |
| EHEC (E. coli O157:H7) | NO ANTIBIOTICS - increases HUS risk | NO loperamide either; supportive care only |
| C. difficile | Stop offending antibiotic; Vancomycin PO or Fidaxomicin | Metronidazole for mild disease |
| Vibrio cholerae | ORS (massive losses); Doxycycline or Azithromycin single dose | IV rehydration often needed given massive secretory losses |
| Giardia | Metronidazole 250 mg QID x 7 days | Nitazoxanide as alternative |
| Cryptosporidium | Nitazoxanide 500 mg bid x 3 days | Immunocompromised: difficult to treat |
| E. histolytica (amebic dysentery) | Metronidazole + Paromomycin (to clear cysts) | Associated with liver abscesses |
Step 8 - When Diarrhea Persists (>7-14 days)
If diarrhea persists after initial evaluation/treatment:
- Reconsider stool studies: Giardia is the most common cause of persistent diarrhea
- Rule out C. difficile (especially if antibiotics recently given)
- Consider Cryptosporidium, Campylobacter, E. histolytica
- If >30 days (chronic): sigmoidoscopy/colonoscopy with biopsies and upper endoscopy with duodenal aspirates may be needed to exclude celiac disease, Crohn's disease, or microscopic colitis (do NOT scope during or immediately after acute enteritis - false positives)
Special Populations
| Population | Key Modifications |
|---|
| Infants/children | ORS is critical; zinc supplementation (resource-limited settings); Azithromycin preferred over fluoroquinolones; AVOID loperamide in young children |
| Elderly ≥70 years | High risk for dehydration and systemic spread; lower threshold for antibiotics and IV fluids |
| Immunocompromised | Always treat with antibiotics even without identified pathogen; consider broader workup including CMV |
| Pregnant | Azithromycin preferred; avoid fluoroquinolones; avoid bismuth subsalicylate |
| Traveler's diarrhea | Rifaximin first-line if noninvasive (not absorbed); Azithromycin if febrile/invasive; avoid TMP-SMX (widespread resistance) |
High-Yield "Avoid" Summary (Exam Favorite)
| Drug | Avoid When | Reason |
|---|
| Loperamide | EHEC, Shigella, febrile dysentery, bloody stools | Prolongs organism clearance; increases HUS risk with EHEC |
| Antibiotics | EHEC O157:H7 | Triggers Shiga toxin release → HUS |
| Bismuth subsalicylate | Immunocompromised, renal impairment, children | Encephalopathy risk; Reye syndrome risk |
| TMP-SMX | Traveler's diarrhea (empiric) | Widespread global resistance |
| Rifaximin | Invasive/febrile traveler's diarrhea | Not absorbed; no systemic activity |
Sources: Harrison's Principles of Internal Medicine 22e, Ch. 49; Goldman-Cecil Medicine (International Ed.); Goodman & Gilman's Pharmacological Basis of Therapeutics; Rosen's Emergency Medicine (Treatment of infectious diarrhea in children); Frameworks for Internal Medicine
Recent guideline note: A 2025 Chinese Pediatric Practice Guideline (PMID 40437180) for acute infectious diarrhea in children reinforces ORS as first-line with selective antibiotic use - consistent with current international standards.